4.7 Review

Consensus on the management of intracranial germ-cell tumours

期刊

LANCET ONCOLOGY
卷 16, 期 9, 页码 E470-E477

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(15)00244-2

关键词

-

类别

资金

  1. Roche
  2. MSD KK
  3. Eisai
  4. Chugai
  5. Nobel Pharma
  6. Merck Sharp and Dohme
  7. Eisai Co, Ltd
  8. Chugai Pharmaceutical Co, Ltd
  9. Medical Research Council [MC_EX_G0800464] Funding Source: researchfish

向作者/读者索取更多资源

The management of intracranial germ-cell tumours is complex because of varied clinical presentations, tumour sites, treatments and outcomes, and the need for multidisciplinary input. Participants of the 2013 Third International CNS Germ Cell Tumour Symposium (Cambridge, UK) agreed to undertake a multidisciplinary Delphi process to identify consensus in the clinical management of intracranial germ-cell tumours. 77 delegates from the symposium were selected as suitable experts in the field and were invited to participate in the Delphi survey, of which 64 (83%) responded to the invitation. Invited participants represented multiple disciplines from Asia, Australasia, Europe, and the Americas. 38 consensus statements encompassing aspects of intracranial germ-cell tumour work-up, staging, treatment, and follow-up were prepared. To achieve consensus, statements required at least 70% agreement from at least 60% of respondents. Overall, 34 (89%) of 38 statements met consensus criteria. This international Delphi approach has defined key areas of consensus that will help guide and streamline clinical management of patients with intracranial germ-cell tumours. Additionally, the Delphi approach identified areas of different understanding and clinical practice internationally in the management of these tumours, areas which should be the focus of future collaborative studies. Such efforts should translate into improved patient outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据